Patents by Inventor Vladimir Khlebnikov
Vladimir Khlebnikov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10500209Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.Type: GrantFiled: November 22, 2017Date of Patent: December 10, 2019Assignee: Zenith Epigenetics Ltd.Inventors: John Frederick Quinn, Vladimir Khlebnikov
-
Patent number: 10272081Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: GrantFiled: January 30, 2018Date of Patent: April 30, 2019Assignee: Aquinox Pharmaceuticals (Canada) Inc.Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Publication number: 20180360828Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: January 30, 2018Publication date: December 20, 2018Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Publication number: 20180161324Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: January 30, 2018Publication date: June 14, 2018Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Patent number: 9937167Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: GrantFiled: December 6, 2016Date of Patent: April 10, 2018Assignee: Aquinox Pharmaceuticals (Canada) Inc.Inventors: Lloyd F. Mackenzie, Thomas B. Macrury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Publication number: 20180092924Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.Type: ApplicationFiled: November 22, 2017Publication date: April 5, 2018Inventors: John Frederick Quinn, Vladimir KHLEBNIKOV
-
Patent number: 9855271Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.Type: GrantFiled: July 30, 2014Date of Patent: January 2, 2018Assignee: Zenith Epigenetics Ltd.Inventors: John Frederick Quinn, Vladimir Khlebnikov
-
Publication number: 20170224682Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: December 6, 2016Publication date: August 10, 2017Inventors: Lloyd F. MACKENZIE, Thomas B. MACRURY, Curtis HARWIG, David BOGUCKI, Jeffery R. RAYMOND, Jeremy D. PETTIGREW, Vladimir KHLEBNIKOV, Rudong SHAN
-
Patent number: 9540353Abstract: Compounds of formula (I): where, n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: GrantFiled: January 7, 2014Date of Patent: January 10, 2017Assignee: Aquinox Pharmaceuticals (Canada) Inc.Inventors: Lloyd F. Mackenzie, Thomas B. Macrury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Publication number: 20160257671Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: January 7, 2014Publication date: September 8, 2016Inventors: Lloyd F. MACKENZIE, Thomas B. MACRURY, Curtis HARWIG, David BOGUCKI, Jeffery R. RAYMOND, Jeremy D. PETTIGREW, Vladimir KHLEBNIKOV, Rudong SHAN
-
Publication number: 20160193218Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.Type: ApplicationFiled: July 30, 2014Publication date: July 7, 2016Inventors: John Frederick QUINN, Vladimir KHLEBNIKOV
-
Publication number: 20150336935Abstract: Compounds of formula (I): where, n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: January 7, 2014Publication date: November 26, 2015Inventors: Lloyd F. MACKENZIE, Thomas B. MACRURY, Curtis HARWIG, David BOGUCKI, Jeffery R. RAYMOND, Jeremy D. PETTIGREW, Vladimir KHLEBNIKOV, Rudong SHAN
-
Patent number: 8101605Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: GrantFiled: December 3, 2010Date of Patent: January 24, 2012Assignee: Aquinox Pharmaceuticals Inc.Inventors: Lloyd Mackenzie, Tom MacRury, Curtis Harwig, Jeremy Pettigrew, Noor Aini Bhatti, Sam Place, Paul Bird, Vladimir Khlebnikov, Rudong Shan
-
Publication number: 20110136802Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: December 3, 2010Publication date: June 9, 2011Applicant: Aquinox Pharmaceuticals Inc.Inventors: Lloyd Mackenzie, Tom MacRury, Curtis Harwig, Jeremy Pettigrew, Noor Aini Bhatti, Sam Place, Paul Bird, Vladimir Khlebnikov, Rudong Shan
-
Publication number: 20030065189Abstract: Starting, for example, from 1-fluoro-2-fluoromethyl-3-butyn-2-yl 4-trifluoromethylphenyl ether, N-(2-cyanoethyl)-5-fluoro-4-fluoromethyl-4-(4-trifluoromethylphenoxy)-2-pentynamide is produced and then cyclized to synthesize 2,2-bis(fluoromethyl)-N-(2-cyanoethyl)-6-trifluoromethyl-2H-1-benzopyran-4-carboxamide. The invention processes for producing 4-substituted benzopyran derivatives involve fewer steps, feature greater safety and allow for easier purification than the prior art processes.Type: ApplicationFiled: August 6, 2002Publication date: April 3, 2003Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Yukio Suzuki, Takenori Ishizawa, Vladimir A. Khlebnikov, Masashi Watanabe
-
Patent number: 6455708Abstract: Starting, for example, from 1-fluoro-2-fluoromethyl-3-butyn-2-yl 4-trifluoromethylphenyl; ether, N-(2-cyanoethyl)-5-fluoro-4-fluoromethyl-4-(4-trifluoromethylphenoxy)-2-pentynamide is produced and then cyclized to synthesize 2,2-bis(fluoromethyl)-N-(2-cyanoethyl)-6-trifluoromethyl-2H-1-benzopyran-4-carboxamide. The invention processes for producing 4-substituted benzopyran derivatives involve fewer steps, feature greater safety and allow for easier purification than the prior art processes.Type: GrantFiled: March 21, 2001Date of Patent: September 24, 2002Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yukio Suzuki, Takenori Ishizawa, Vladimir A. Khlebnikov, Masashi Watanabe